New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.

Niki, Maiko; Yokoi, Takashi; Kurata, Takayasu; Nomura, Shosaku

Niki, Maiko; Yokoi, Takashi; Kurata, Takayasu; Nomura, Shosaku.

Afiliação

Niki M; First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Yokoi T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Kurata T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Nomura S; First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.

Lung Cancer (Auckl) ; 8: 91-99, 2017.

Article em En | MEDLINE | ID: mdl-28814907

Palavras-chave

HMGB1; PAI-1; bevacizumab; non-small-cell lung cancer; platelet-derived microparticle

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Lung Cancer (Auckl) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google